One of the world's top vaccine makers is partnering with a leading AI company to advance medical care, and the company's chief executive is excited.
Moderna and OpenAI announced an ongoing partnership Wednesday. Incorporating AI across Moderna’s business, provides access to ChatGPT Enterprise for teams including legal, research, and manufacturing.the company said Integrating AI into your business has the potential to exceed expectations According to the Wall Street Journal, the company plans to launch 15 new products over the next five years.
Stéphane Bancel, CEO of Moderna, told WSJ that the partnership is key to advancing the vaccine maker's business processes, adding that Moderna's ability to move beyond COVID-19 vaccines to similar as we move to produce other mRNA medicines that can prevent cancer and treat cancer. Bancel told the Journal that he has been hooked on ChatGPT since its release in late 2022, and that his goal is for Moderna employees to use ChatGPT at least 20 times a day. He added that employees are keen to use chatbots at work.
“Just as the introduction of personal computers in the 1980s changed the way we work and live, AI is on a path to completely change our daily lives, and OpenAI is helping lead the way. “We are doing so,” Bancel said. statement. “Moderna has ambitious plans to launch multiple products over the next few years, and collaborations with companies like OpenAI will help us scale and maximize patient impact.” It’s essential.”
The collaboration between Moderna and OpenAI began in 2023. Launch of Moderna version of ChatGPT called mChat. Since then, Moderna has deployed more than 750 GPTs (Generative Pre-Trained Transformers) to automate its business, including a GPT tailored to select doses for clinical trials. GPT is a type of Large Language Model (LLM) developed by OpenAI.
“Moderna is leading the way by empowering all employees to leverage AI to address complex problems,” OpenAI CEO Sam Altman said in a statement. . “We look forward to continuing to work with Moderna to bring a new generation of medicines to patients in need.”
